10-K Filing

MERCK & CO., INC. CIK: 310158 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001628280-24-006850`
Period End Date	20231231
Filing Date	20240226
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	mrk-20231231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 90 Income Statement 60 Cash Flow Statement 147 Stockholders Equity 32 Comprehensive Income 18

Balance Sheet 90 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$88.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$72.00M	USD	Point-in-time
Inventory classified in Other assets	`InventoryNoncurrent`	$3.35B	USD	Point-in-time
Inventory classified in Other assets	`InventoryNoncurrent`	$2.94B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.69B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.84B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, authorized (in shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$252.00M	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$498.00M	USD	Point-in-time
Common stock, authorized (in shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $88 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$10.35B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $88 in 2023 and $72 in 2022)	`AccountsReceivableNetCurrent`	$9.45B	USD	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Inventories (excludes inventories of $3,348 in 2023 and $2,938 in 2022 classified in Other assets - see Note 8)	`InventoryNet`	$5.91B	USD	Point-in-time
Inventories (excludes inventories of $3,348 in 2023 and $2,938 in 2022 classified in Other assets - see Note 8)	`InventoryNet`	$6.36B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.37B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$35.72B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$32.17B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.01B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$252.00M	USD	Point-in-time
Land	`Land`	$326.00M	USD	Point-in-time
Land	`Land`	$295.00M	USD	Point-in-time
Buildings	`BuildingsAndImprovementsGross`	$13.17B	USD	Point-in-time
Buildings	`BuildingsAndImprovementsGross`	$14.97B	USD	Point-in-time
Machinery, equipment and office furnishings	`MachineryAndEquipmentGross`	$16.76B	USD	Point-in-time
Machinery, equipment and office furnishings	`MachineryAndEquipmentGross`	$17.76B	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$9.19B	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$8.26B	USD	Point-in-time
Property, plant and equipment (at cost)	`PropertyPlantAndEquipmentGross`	$41.32B	USD	Point-in-time
Property, plant and equipment (at cost)	`PropertyPlantAndEquipmentGross`	$39.41B	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.27B	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.98B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$19.28B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$21.42B	USD	Point-in-time
Goodwill	`Goodwill`	$21.26B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$18.01B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$20.27B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.00B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$9.53B	USD	Point-in-time
Total Assets	`Assets`	$106.67B	USD	Point-in-time
Total Assets	`Assets`	$109.16B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.95B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.37B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.92B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.26B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.16B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$15.77B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.65B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.99B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.99B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.88B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.69B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$24.24B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$28.75B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$33.68B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.79B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$871.00M	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.32B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.38B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.51B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$61.08B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$53.90B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.16B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.77B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$102.48B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.03B	USD	Point-in-time
Less treasury stock, at cost: 1,045,470,249 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Less treasury stock, at cost: 1,045,470,249 shares in 2023 and 1,039,269,638 shares in 2022	`TreasuryStockCommonValue`	$56.49B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$45.99B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$37.58B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$54.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$67.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$109.16B	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$106.67B	USD	Point-in-time

Income Statement 60 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$60.12B	USD	Annual
Sales	`Revenues`	$48.70B	USD	Annual
Sales	`Revenues`	$59.28B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$13.63B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$16.13B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$17.41B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$9.63B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.04B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.50B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$13.55B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$30.53B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$12.24B	USD	Annual
Restructuring costs	`RestructuringCharges`	$599.00M	USD	Annual
Restructuring costs	`RestructuringCharges`	$337.00M	USD	Annual
Restructuring costs	`RestructuringCharges`	$661.00M	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$1.34B	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-1.50B	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-466.00M	USD	Annual
Total costs, expenses and other	`CostsExpensesAndOther`	$34.83B	USD	Annual
Total costs, expenses and other	`CostsExpensesAndOther`	$42.84B	USD	Annual
Total costs, expenses and other	`CostsExpensesAndOther`	$58.23B	USD	Annual
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$16.44B	USD	Annual
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$1.89B	USD	Annual
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$13.88B	USD	Annual
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$1.52B	USD	Annual
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$1.51B	USD	Annual
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$1.92B	USD	Annual
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$12.36B	USD	Annual
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$14.53B	USD	Annual
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$377.00M	USD	Annual
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$7.00M	USD	Annual
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$13.00M	USD	Annual
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$12.00M	USD	Annual
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$12.35B	USD	Annual
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$14.52B	USD	Annual
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$365.00M	USD	Annual
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$704.00M	USD	Annual
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	Annual
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$365.00M	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.05B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$14.52B	USD	Annual
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$0.14	USD	Annual
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$4.88	USD	Annual
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$5.73	USD	Annual
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.28	USD	Annual
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	-	USD	Annual
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	-	USD	Annual
Net Income (in dollars per share)	`EarningsPerShareBasic`	$5.16	USD	Annual
Net Income (in dollars per share)	`EarningsPerShareBasic`	$5.73	USD	Annual
Net Income (in dollars per share)	`EarningsPerShareBasic`	$0.14	USD	Annual
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$4.86	USD	Annual
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$0.14	USD	Annual
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$5.71	USD	Annual
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare`	-	USD	Annual
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare`	$0.28	USD	Annual
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare`	-	USD	Annual
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$5.71	USD	Annual
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$0.14	USD	Annual
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$5.14	USD	Annual

Cash Flow Statement 147 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCash`	$71.00M	USD	Point-in-time
Restricted cash	`RestrictedCash`	$68.00M	USD	Point-in-time
Restricted cash	`RestrictedCash`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCash`	$103.00M	USD	Point-in-time
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$12.36B	USD	Annual
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$14.53B	USD	Annual
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$377.00M	USD	Annual
Amortization	`AdjustmentForAmortization`	$1.64B	USD	Annual
Amortization	`AdjustmentForAmortization`	$2.08B	USD	Annual
Amortization	`AdjustmentForAmortization`	$2.04B	USD	Annual
Depreciation	`Depreciation`	$1.58B	USD	Annual
Depreciation	`Depreciation`	$1.83B	USD	Annual
Depreciation	`Depreciation`	$1.82B	USD	Annual
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$1.75B	USD	Annual
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$302.00M	USD	Annual
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$792.00M	USD	Annual
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-1.42B	USD	Annual
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$1.94B	USD	Annual
(Income) loss from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$340.00M	USD	Annual
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree`	$10.22B	USD	Annual
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree`	-	USD	Annual
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionThree`	-	USD	Annual
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	-	USD	Annual
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	-	USD	Annual
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	$1.19B	USD	Annual
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	Annual
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	Annual
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.56B	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$187.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.90B	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.57B	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$541.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$645.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$479.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-1.30B	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-805.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-355.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.15B	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$2.03B	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$644.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$674.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$816.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$161.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-380.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$405.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-289.00M	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$277.00M	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$1.78B	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-50.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-540.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$380.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$214.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-545.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$484.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$456.00M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$1.47B	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$1.76B	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$2.31B	USD	Annual
Net Cash Provided by Operating Activities of Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$13.01B	USD	Annual
Net Cash Provided by Operating Activities of Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$13.12B	USD	Annual
Net Cash Provided by Operating Activities of Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$19.09B	USD	Annual
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.39B	USD	Annual
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.45B	USD	Annual
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$3.86B	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$955.00M	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$1.00M	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$1.20B	USD	Annual
Proceeds from sale of Seagen Inc. common stock	`ProceedsFromSaleOfEquitySecuritiesFvNi`	-	USD	Annual
Proceeds from sale of Seagen Inc. common stock	`ProceedsFromSaleOfEquitySecuritiesFvNi`	$1.15B	USD	Annual
Proceeds from sale of Seagen Inc. common stock	`ProceedsFromSaleOfEquitySecuritiesFvNi`	-	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$1.03B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$1.66B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$721.00M	USD	Annual
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	-	USD	Annual
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	-	USD	Annual
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	$10.71B	USD	Annual
Acquisition of Imago BioSciences Inc., net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	-	USD	Annual
Acquisition of Imago BioSciences Inc., net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	-	USD	Annual
Acquisition of Imago BioSciences Inc., net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	$1.33B	USD	Annual
Acquisition of Acceleron Pharma Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	Annual
Acquisition of Acceleron Pharma Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$11.17B	USD	Annual
Acquisition of Acceleron Pharma Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	Annual
Acquisition of Pandion Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$1.55B	USD	Annual
Acquisition of Pandion Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	Annual
Acquisition of Pandion Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	Annual
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$121.00M	USD	Annual
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	Annual
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$179.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-32.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$36.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$91.00M	USD	Annual
Net Cash Used in Investing Activities of Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-14.08B	USD	Annual
Net Cash Used in Investing Activities of Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-4.96B	USD	Annual
Net Cash Used in Investing Activities of Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-16.42B	USD	Annual
Net change in short-term borrowings	`RepaymentsOfShortTermDebt`	$3.99B	USD	Annual
Net change in short-term borrowings	`RepaymentsOfShortTermDebt`	-	USD	Annual
Net change in short-term borrowings	`RepaymentsOfShortTermDebt`	-	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$2.25B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$2.32B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$1.75B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$7.94B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$5.94B	USD	Annual
Distribution from Organon & Co.	`DisposalGroupIncludingDiscontinuedOperationsDistributionReceived`	-	USD	Annual
Distribution from Organon & Co.	`DisposalGroupIncludingDiscontinuedOperationsDistributionReceived`	$9.00B	USD	Annual
Distribution from Organon & Co.	`DisposalGroupIncludingDiscontinuedOperationsDistributionReceived`	-	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$840.00M	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$1.35B	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$7.01B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$6.61B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$7.45B	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$202.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$125.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$384.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-286.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-240.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-328.00M	USD	Annual
Net Cash (Used in) Provided by Financing Activities of Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-9.12B	USD	Annual
Net Cash (Used in) Provided by Financing Activities of Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$3.10B	USD	Annual
Net Cash (Used in) Provided by Financing Activities of Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-4.81B	USD	Annual
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	-	USD	Annual
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	-	USD	Annual
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$987.00M	USD	Annual
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	-	USD	Annual
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$-134.00M	USD	Annual
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	-	USD	Annual
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	-	USD	Annual
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	$-504.00M	USD	Annual
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	-	USD	Annual
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	-	USD	Annual
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	-	USD	Annual
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	$349.00M	USD	Annual
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.00M	USD	Annual
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-410.00M	USD	Annual
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-133.00M	USD	Annual
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-5.86B	USD	Annual
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$14.00M	USD	Annual
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$4.61B	USD	Annual
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $79, $71 and $103 of restricted cash at January 1, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $79, $71 and $103 of restricted cash at January 1, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $79, $71 and $103 of restricted cash at January 1, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $79, $71 and $103 of restricted cash at January 1, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $68, $79 and $71 of restricted cash at December 31, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $68, $79 and $71 of restricted cash at December 31, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $68, $79 and $71 of restricted cash at December 31, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $68, $79 and $71 of restricted cash at December 31, 2023, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time

Stockholders Equity 32 line items

Line Item	Tag	Value	Unit	Period
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.64	USD	Annual
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.80	USD	Annual
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.96	USD	Annual
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$365.00M	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.05B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$14.52B	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-339.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-393.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$1.76B	USD	Annual
Cash dividends declared on common stock	`DividendsCommonStockCash`	$6.71B	USD	Annual
Cash dividends declared on common stock	`DividendsCommonStockCash`	$7.13B	USD	Annual
Cash dividends declared on common stock	`DividendsCommonStockCash`	$7.55B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$1.35B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$840.00M	USD	Annual
Spin-off of Organon & Co.	`StockholdersEquityNoteSpinoffTransaction`	$5.09B	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$16.00M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$7.00M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$12.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$25.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$13.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$29.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$-525.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$-761.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$-515.00M	USD	Annual
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time

Comprehensive Income 18 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$365.00M	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.05B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$14.52B	USD	Annual
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$410.00M	USD	Annual
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-71.00M	USD	Annual
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-97.00M	USD	Annual
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$385.00M	USD	Annual
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-335.00M	USD	Annual
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-1.77B	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-423.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$89.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-603.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-339.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$1.76B	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-393.00M	USD	Annual
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$-28.00M	USD	Annual
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$14.80B	USD	Annual
Comprehensive (Loss) Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$14.18B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.